部分HPV16/18分型在宫颈癌筛查风险分层中的临床相关性:基于人群的队列研究
该研究基于意大利组织性宫颈癌筛查项目,纳入2015-2019年高危HPV感染女性,分析部分HPV16/18分型与细胞学分流及组织学确诊CIN3+的关联。结果显示HPV16感染女性累积CIN3+检出率9.8%,高于HPV18的3.4%和其他型别的1.8%;HPV16分型联合高级别细胞学可作为分流生物标志物。
要点
- HPV16感染女性CIN3+累积检出率9.8%,显著高于其他型别。
- HPV18行为与其他HPV型别相似,不提供额外风险分层。
- HPV16分型联合高级别细胞学可优化CIN3+检出并减少阴道镜。
核心结论
- 部分HPV16分型可能在分流中发挥作用,而HPV18与其他HPV型别行为相似,不提供额外分层。
- HPV16分型联合高级别细胞学可被视为宫颈筛查中的分流生物标志物,以最大化CIN3+检出同时最小化基线或1年复查的阴道镜。
研究设计与样本
- 基于人群的队列研究,纳入意大利组织性宫颈癌筛查项目中2015-2019年高危HPV感染女性。
主要发现
- HPV16和HPV18分别存在于1865和594份样本中。
- 累积(基线加1年复查)细胞学阳性率为42.8%,基线HPV16感染女性高级别细胞学显著更高(15.2%,P < 0.0001)。
- HPV16、HPV18和其他HPV型别感染女性的累积CIN3+检出率分别为9.8%、3.4%和1.8%。
关键数值与推荐
- HPV16感染女性累积CIN3+检出率9.8%,HPV18为3.4%,其他HPV型别为1.8%。
- 基线HPV16感染女性高级别细胞学比例为15.2%,显著高于其他(P < 0.0001)。
- 累积细胞学阳性率为42.8%。
临床怎么用
- 对于HPV阳性女性,可考虑使用HPV16分型联合高级别细胞学进行分流,以识别高风险女性转诊阴道镜。
- HPV18分型不提供额外风险分层,可能无需单独用于分流。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate partial HPV16/18 genotyping as a possible biomarker to select women attending HPV-based cervical cancer screening at higher risk to be referred to colposcopy. DESIGN: Population-based cohort study. SETTING: Organised cervical cancer screening programmes (Italy). POPULATION: Women with high-risk HPV infection (period: 2015-2019). METHODS: We analysed the association between partial HPV16/18 genotyping, cytology triage and histologically confirmed diagnosis of high-grade cervical intraepithelial neoplasia (CIN3+ ) lesions. MAIN OUTCOME MEASURES: Detection rate (DR) and positive predictive value (PPV) for histologically confirmed CIN3+ (any episode in the 2 years after baseline); sensitivity for CIN3+ and number of colposcopies needed for lesion detection. RESULTS: The study included 145 437 women screened with HPV testing by the clinically validated COBAS 4800 HPV assay (Roche). Overall, 9601 (6.6%) women were HPV+ at baseline; HPV16 and HPV18 were present in 1865 and 594 samples, respectively. The cumulative (baseline plus 1-year repeat) cytology positivity was 42.8% and high-grade cytology was significantly higher (P < 0.0001) among women with HPV16 infection at baseline (15.2%). The cumulative CIN3+ DR for women with HPV16, HPV18 and other HPV-type infections was 9.8%, 3.4% and 1.8%, respectively. CONCLUSIONS: Partial HPV16 genotyping may play a role in triage, whereas HPV18 seems to behave much more similarly to the other HPV types and does not provide additional stratification. HPV16 genotyping combined with high-grade cytology can be envisaged as a triage biomarker in cervical screening to maximise CIN3+ detection while minimising colposcopy at baseline or 1-year repeat. TWEETABLE ABSTRACT: HPV16 genotyping combined with high-grade cytology can be used as triage biomarker for CIN3+ in HPV-positive women.
引用
- Gori S, Battagello J, Gustinucci D, et al. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study. BJOG. 2021. PMID: 33326680. doi:10.1111/1471-0528.16631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。